IncyteMEX:INCY 84 FCF Yield % is 6.25 as of Jun. 29, 2026, which is 151% above its 10-year median of 2.49. GuruFocus rates MEX:INCY with a GF Score™ of 84/100 and a GF Value™ of MXN1,464.02 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 1,416 Biotechnology companies, Incyte ranks better than 94.77% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, Incyte's Trailing 12-Month Free Cash Flow is MXN25,806 Mil, and Market Cap is MXN398,107 Mil. Therefore, Incyte's FCF Yield % for today is 6.25%.
The historical rank and industry rank for Incyte's FCF Yield % or its related term are showing as below:
MEX:INCY'
s FCF Yield % Range Over the Past 10 Years
Min: -1.81 Med: 2.49 Max: 7.26
Current: 6.25
During the past 13 years, the highest FCF Yield % of Incyte was 7.26%. The lowest was -1.81%. And the median was 2.49%.
MEX:INCY's FCF Yield % is ranked better than 94.77% of 1416
companies
in the Biotechnology industry
Industry Median: -9.62
vs MEX:INCY: 6.25
Incyte's FCF Margin % for the quarter that ended in Mar. 2026 was 27.83%.
Incyte FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Incyte FCF Yield % Related Terms
Incyte FCF Yield % Historical Data
* Premium members only.
The historical data trend for Incyte's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:INCY vs INSM, BNTX, ROIV: FCF Yield % Comparison
For the Biotechnology subindustry, Incyte's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Incyte FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Incyte's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Incyte's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Incyte (MEX:INCY) has a FCF Yield % of 6.25 as of Jun. 29, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Incyte and its competitors. This is 151% above median its historical median of 2.49. According to the industry distribution chart, Incyte ranks #74 out of 1416 companies in the Biotechnology industry, placing it in the top 5.2%.
Is Incyte's FCF Yield % too high?
Incyte's current FCF Yield % of 6.25 is 151% above median its 10-year median of 2.49. Based on the distribution chart, Incyte ranks #74 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Incyte has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Incyte's FCF Yield % compare to INSM and BNTX?
According to the Biotechnology industry distribution chart, Incyte ranks #74 out of 1416 companies for FCF Yield %. This places Incyte in the top 5% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Incyte and its competitors. Incyte's current FCF Yield % is 6.25, which is 151% above median its own 10-year median of 2.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Incyte stock overvalued right now?
Based on GuruFocus' analysis, Incyte (MEX:INCY) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN1,464.02, compared to a current price of MXN1,676.03 — trading 14.5% above its estimated fair value. The current FCF Yield % is 6.25, which is 151% above median its 10-year median of 2.49. Incyte's overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Incyte (MEX:INCY), the current FCF Yield % is 6.25 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Incyte (MEX:INCY) Overvalued in 2026?
Based on GuruFocus' analysis, Incyte stock appears to be overvalued.
The current stock price of MXN1,676.03 is trading 14.5% above its estimated GF Value™ of MXN1,464.02.
GuruFocus considers Incyte to be Modestly Overvalued.
Key valuation signals for MEX:INCY:
FCF Yield %: 6.25 (151% above median its 10-year median of 2.49)
GF Value™: MXN1,464.02 vs. price of MXN1,676.03 (14.5% above fair value)
No single metric tells the full story. See the MEX:INCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
84GF Score
Get the complete analysis for MEX:INCY
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:INCY has been successfully added to your 
